eXoZymes (EXOZ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Sep, 2026Executive summary
Annual meeting scheduled for November 13, 2026, with voting open until November 12, 2026.
Shareholders can access proxy materials online or request paper/email copies before October 30, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of six nominees to serve as directors until the 2027 annual meeting.
Ratification of RBSM LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Provision to transact other business that may properly come before the meeting or any adjournments.
Board of directors and corporate governance
Six director nominees: Christopher A. Marlett, Anthony DiGiandomenico, Edgardo Rayo, James J. Lalonde, James U. Bowie, and Lon E. Bell.
Latest events from eXoZymes
- Virtual meeting to elect directors and ratify auditor, with strong governance and oversight.EXOZ
Proxy filing - 10x NCT productivity gain, $5.65M cash, but long-term funding uncertainty persists.EXOZ
Q2 2026 - Net loss increased 27.7% year-over-year as cash reserves declined and funding needs intensified.EXOZ
Q1 2026 - AI-driven cell-free platform delivers rare molecules at scale, targeting multi-billion-dollar markets.EXOZ
Investor presentation - Cell-free biomanufacturing platform targets $200B+ markets with rapid, high-purity product launches.EXOZ
Investor presentation - Cell-free biomanufacturing platform targets $200B+ markets with rapid, scalable product launches.EXOZ
Investor presentation - Scalable NCT production unlocks new metabolic health solutions for global wellness and pharma markets.EXOZ
Investor presentation - NCT reached kilo-scale production as operating expenses rose and financing preparations advanced.EXOZ
Q4 2025 - Shelf registration for $50M in securities supports cell-free biotech growth amid high risk.EXOZ
Registration Filing